米那普明用于显著改善一名无抑郁症状患者的难治性疼痛：一例病例报告。 - Suppr | 超能文献

Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.

作者信息

Kito Shinsuke, Nakajima Toru, Koga Yoshihiko

出版信息

Eur Psychiatry. 2005 Jun;20(4):355. doi: 10.1016/j.eurpsy.2005.04.005.

DOI:10.1016/j.eurpsy.2005.04.005

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Milnacipran for the drastic improvement of refractory pain in a patient without depressive symptoms: a case report.米那普明用于显著改善一名无抑郁症状患者的难治性疼痛：一例病例报告。

Eur Psychiatry. 2005 Jun;20(4):355. doi: 10.1016/j.eurpsy.2005.04.005.

2

Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain.血清素与去甲肾上腺素再摄取抑制剂米那普明在疼痛治疗中的临床潜力。

Curr Opin Investig Drugs. 2006 Jul;7(7):637-42.

3

Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.

Hum Psychopharmacol. 2002 Jun;17(4):195-6. doi: 10.1002/hup.392.

4

The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.鞘内注射米那普明（一种5-羟色胺去甲肾上腺素再摄取抑制剂）在神经性疼痛大鼠模型中由单胺介导的抗痛觉过敏作用。

Anesth Analg. 2005 May;100(5):1406-1410. doi: 10.1213/01.ANE.0000149546.97299.A2.

5

Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.血清素-去甲肾上腺素再摄取抑制剂（SNRI）米那普明对选择性血清素再摄取抑制剂（SSRI）反应不足的帕金森病患者抑郁症状有显著疗效：两例病例报告。

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):351-3. doi: 10.1016/j.pnpbp.2004.11.023. Epub 2004 Dec 29.

6

Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.米那普明，一种新型5-羟色胺和去甲肾上腺素再摄取抑制剂：其抗抑郁活性及临床耐受性概述

Int Clin Psychopharmacol. 1997 Mar;12(2):99-108. doi: 10.1097/00004850-199703000-00005.

7

Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region.米那普明治疗口面部区域慢性疼痛的有效性。

Clin Neuropharmacol. 2010 Mar-Apr;33(2):79-83. doi: 10.1097/WNF.0b013e3181cb5793.

8

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.米那普明和帕罗西汀治疗后抑郁症患者出现的治疗后新发不良事件。

Hum Psychopharmacol. 2004 Dec;19(8):585-6. doi: 10.1002/hup.644.

9

Clinical efficacy of milnacipran: placebo-controlled trials.米那普明的临床疗效：安慰剂对照试验。

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:29-33. doi: 10.1097/00004850-199609004-00004.

10

Milnacipran for the treatment of chronic pain.米那普明用于治疗慢性疼痛。

Hum Psychopharmacol. 2003 Oct;18(7):575-6. doi: 10.1002/hup.521.

引用本文的文献

1

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.日本对米那普仑（日本首个 5-羟色胺和去甲肾上腺素再摄取抑制剂）的应用经验。

Neuropsychiatr Dis Treat. 2007 Feb;3(1):41-58. doi: 10.2147/nedt.2007.3.1.41.